A modern clinic for at-home treatments
(857) 240-1080
Holiday Sale! Get started today for only
$49 $4.99
Written and prepared by:
Rebuma Firdessa-Fite, Stephanie N. Johnson, Martin A. Leon, Joshua O. Sestak, Cory Berkland, Remi J. Creusot
Discover how soluble antigen arrays (SAgAs) enhance the safety and efficacy of peptide-based immunotherapy for autoimmune diabetes. This study highlights SAgAs' superiority over free peptides in preventing diabetes, increasing regulatory T cells, and reducing anaphylaxis risk in the NOD mouse model. The findings suggest promising advancements for targeted autoimmune therapies using modified peptides.
Exploring the use of soluble antigen arrays to improve peptide-based immunotherapy for autoimmune diseases.
Study on the efficacy and safety improvements of soluble antigen arrays compared to free peptides.
Detailed analysis of how soluble antigen arrays influence immune responses and prevent autoimmune diabetes.
Examining how different peptide modifications affect the incidence and severity of anaphylaxis in immunotherapy.
Comparison of hydrolysable and non-hydrolysable soluble antigen arrays versus free peptides in treating autoimmune diseases.
Insights into how soluble antigen arrays induce regulatory T cells and improve immunotherapy outcomes.
Insurance covers clinical consultations.
Subscription fee (from $59/month not billed to insurance) covers immunotherapy, shipping & related costs.